Resveratrol has antiinflammatory and antifibrotic effects in the peptidoglycan-polysaccharide rat model of Crohn's disease

Inflammatory Bowel Diseases

Volumn 18, Issue 4, 2012, Pages 613-623

  Rahal, Kinan ^a   Schmiedlin Ren, Phyllissa ^a   Adler, Jeremy ^a   Dhanani, Muhammad ^a   Sultani, Victoria ^a,c   Rittershaus, Ahren C ^a   Reingold, Laura ^a   Zhu, Ji ^b   McKenna, Barbara J ^a   Christman, Gregory M ^a   Zimmermann, Ellen M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

Fibrosis; Inflammation; Inflammatory bowel disease; Stricture

Indexed keywords

COLLAGEN; CYTOKINE; GROWTH FACTOR; HUMAN SERUM ALBUMIN; MESSENGER RNA; PEPTIDOGLYCAN POLYSACCHARIDE; PROCOLLAGEN; PROCOLLAGEN TYPE 1; PROCOLLAGEN TYPE 3; RESVERATROL; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DOSE RESPONSE; DRUG EFFECT; ENTERITIS; FEMALE; HEMOSTASIS; INTESTINAL FIBROSIS; LAPAROTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLON; CROHN DISEASE; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; FIBROSIS; ILEUM; PEPTIDOGLYCAN; POLYSACCHARIDES; PROCOLLAGEN; RATS; RATS, INBRED LEW; SERUM ALBUMIN; STILBENES;

EID: 84858705832     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21843     Document Type: Article

References (55)

1. Goswami SK, Das DK. Resveratrol and chemoprevention. Cancer Lett. 2009;284:1-6.
2. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997;275:218-220. (Pubitemid 127696281)
3. Sgambato A, Ardito R, Faraglia B, et al. Resveratrol, a natural phenolic compound, inhibits cell proliferation and prevents oxidative DNA damage. Mutat Res. 2001;496:171-180. (Pubitemid 32718779)
4. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5:493-506. (Pubitemid 44136961)
5. de la Lastra CA, Villegas I. Resveratrol as an anti-inflammatory and anti-aging agent: Mechanisms and clinical implications. Mol Nutr Food Res. 2005;49:405-430. (Pubitemid 40780389)
6. Li ZG, Hong T, Shimada Y, et al. Suppression of N-nitrosomethylben- zylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol. Carcinogenesis. 2002;23:1531-1536. (Pubitemid 35012434)
7. Sengottuvelan M, Viswanathan P, Nalini N. Chemopreventive effect of trans-resveratrol - a phytoalexin - against colonic aberrant crypt foci and cell proliferation in 1,2-dimehtylhydrazine induced colon carcinogenesis. Carcinogenesis. 2006;27:1038-1046.
8. Tessitore L, Davit A, Sarotto I, et al. Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21CIP expression. Carcinogenesis. 2000;21:1619-1622. (Pubitemid 30608219)
9. Banerejee S, Bueso-Ramos C, Aggarwal BB. Suppression of 7,12- dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-jB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res. 2002;62:4945-4954. (Pubitemid 34984418)
10. Wood LG, Wark PAB, Garg ML. Antioxidant and anti-inflammatory effects of resveratrol in airway disease. Antioxid Redox Signal. 2010;13:1535-1548.
11. Losso JN, Truax RE, Richard G. trans-Resveratrol inhibits hyperglycemia- induced inflammation and connexin downregulation in retinal pigment epithelial cells. J Agric Food Chem. 2010;58:8246-8252.
12. Larrosa M, Yañéz-Gascón MJ, Selma MV, et al. Effect of a low dose of dietary resveratrol on colon microbiota, inflammation and tissue damage in a DSS-induced colitis rat model. J Agric Food Chem. 2009;57:2211-2220.
13. Cui X, Jin Y, Hofseth AB, et al. Resveratrol suppresses colitis and colon cancer associated with colitis. Cancer Prev Res. 2010;3:549-559.
14. Youn J, Lee J-S, Na H-K, et al. Resveratrol and piceatannol inhibit iNOS expression and NF-jB activation in dextran sulfate sodium-induced mouse colitis. Nutr Cancer. 2009;61:847-854.
15. Singh UP, Singh NP, Singh B, et al. Resveratrol (trans-3,5,4′- trihydroxystilbene) induces silent mating type information regulation-1 and down-regulates nuclear transcription factor-jB activation to abrogate dextran sulfate sodium-induced colitis. J Pharmacol Exp Ther. 2010;332:829-839.
16. Sánchez-Fidalgo S, Cárdeno A, Villegas I, et al. Dietary supplementation of resveratrol attenuates chronic colonic inflammation in mice. Eur J Pharmacol. 2010;633:78-84.
17. Martín AR, Villegas I, Sánchez-Hidalgo M, et al. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br J Pharmacol. 2006;147:873-885.
18. Uguralp S, Irsi C, Aksoy T, et al. Resveratrol attenuates inflammation and stricture formation in experimental caustic esophageal burns. Pediatr Surg Int. 2008;24:425-430.
19. Chavez E, Reyes-Gordillo K, Segovia J, et al. Resveratrol prevents fibrosis, NF-jB activation and TGF-b increases induced by chronic CCL4 treatment in rats. J Appl Toxicol. 2008;28:35-43.
20. Lee E-S, Shin M-O, Yoon S, et al. Resveratrol inhibits dimethylnitrosamine- induced hepatic fibrosis in rats. Arch Pharm Res. 2010;33:925-932.
21. Hong S-W, Jung KH, Zheng H-M, et al. The protective effect of resveratrol on dimethylnitrosamine-induced liver fibrosis in rats. Arch Pharm Res. 2010;33:601-609.
22. Li J, Qu X, Ricardo SD, et al. Resveratrol inhibits renal fibrosis in the obstructed kidney. Am J Pathol. 2010;177:1065-1071.
23. Sutra T, Oiry C, Azay-Milhau J, et al. Preventive effects of nutritional doses of polyphenolic molecules on cardiac fibrosis associated with metabolic syndrome: involvement of osteopontin and oxidative stress. J Agric Food Chem. 2008;56:11683-11687.
24. Jing Y-H, Chen K-H, Yang S-H, et al. Resveratrol ameliorates vasculopathy in STZ-induced diabetic rats: role of AGE-RAGE signalling. Diabetes Metab Res Rev. 2010;26:212-222.
25. Zou J, Huang Y, Cao K, et al. Effect of resveratrol on intimal hyperplasia after endothelial denudation in an experimental rabbit model. Life Sci. 2000;68:153-163.
26. Garcia P, Schmiedlin-Ren P, Mathias JS, et al. Resveratrol causes cell cycle arrest, decreased collagen synthesis, and apoptosis in rat intestinal smooth muscle cells. Am J Physiol Gastrointest Liver Physiol. (in press).
27. Sartor RB, Cromartie WJ, Powell DW, et al. Granulomatous enterocolitis induced in rats by purified bacterial cell wall fragments. Gastroenterology. 1985;89:587-596.
28. Zimmermann EM, Sartor RB, McCall RD, et al. Insulin-like growth factor I and interleukin 1b messenger RNA in a rat model of granulomatous enterocolitis and hepatitis. Gastroenterology. 1993;105:399-409. (Pubitemid 23213524)
29. Adler J, Swanson SD, Schmiedlin-Ren P, et al. Magnetization transfer helps detect intestinal fibrosis in an animal model of Crohn disease. Radiology. 2011;259:127-135.
30. International Commission on Illumination. Proceedings of the CIE Expert Symposium 097 on Colour Standards for Image Technology. Vienna, Austria: Commission Internationale de l'éclairage, CIE Central Bureau, 1998.
31. Schwartz MW, Cowan WB, Beatty JC. An experimental comparison of RGB, YIQ, LAB, HSV, and opponent color models. ACM Trans Graph. 1987;6:123-158.
32. Burke JP, Muslow JJ, O'Keane C, et al. Fibrogenesis in Crohn's disease. Am J Gastroenterol. 2007;102:439-448. (Pubitemid 46160558)
33. Shankar S, Gyanendra G, Srivastava RK. Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Frontiers Biosci. 2007;12:4839-4854.
34. Kolgazi M, Şener G, Çetinel Ş, et al. Resveratrol reduces renal and lung injury caused by sepsis in rats. J Surg Res. 2006;134:315-321. (Pubitemid 44092800)
35. Isaacs KL, Sartor RB, Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology. 1992;103:1587-1595.
36. Inohara N, Ogura Y, Fontalba A, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem. 2003;278:5509-5512. (Pubitemid 36800790)
37. Crowell JA, Korytko PJ, Morrissey RL, et al. Resveratrol-associated renal toxicity. Toxicol Sci. 2004;82:614-619. (Pubitemid 39600090)
38. Hebbar V, Shen G, Hu R, et al. Toxicogenomics of resveratrol in rat liver. Life Sci. 2005;76:2299-2314. (Pubitemid 40313418)
39. Zimmermann EM, Li L, Hou YT, et al. Insulin-like growth factor I and insulin-like growth factor binding protein 5 in Crohn's disease. Am J Physiol Gastrointest Liver Physiol. 2001;280:G1022-G1029.
40. Pucilowska JB, McNaughton KK, Mohapatra NK, et al. IGF-I and procollagen a1(I) are co-expressed in a subset of mesenchymal cells in active Crohn's disease. Am J Physiol Gastrointest Liver Physiol. 2000;279:G1307-G1322.
41. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 2000;92: 1472-1489.
42. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst. 2002;94:972-980. (Pubitemid 34814726)
43. Patel KR, Brown VA, Jones DJL, et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 2010;70:7392-7399.
44. Brown VA, Patel KR, Viskaduraki M, et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 2010;70:9003-9011.
45. Xie J, Itzkowitz SH. Cancer in inflammatory bowel disease. World J Gastroenterol. 2008;14:378-389. (Pubitemid 351320846)
46. Marier J-F, Vachon P, Gritsas A, et al. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther. 2002;302:369-373. (Pubitemid 34680460)
47. Yu C, Shin YG, Chow A, et al. Human, rat, and mouse metabolism of resveratrol. Pharm Res. 2002;19:1907-1914. (Pubitemid 36016041)
48. Boocock DJ, Faust GES, Patel KR, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev. 2007;16:1246-1252. (Pubitemid 46984966)
49. Almeida L, Vaz-da-Silva M, Falcão A, et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res. 2009;53:S7-S15.
50. Calamini B, Ratia K, Malkowski MG, et al. Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem J. 2010;429:273-282.
51. Hoshino J, Park E-J, Kondratyuk TP, et al. Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem. 2010;53:5033-5043.
52. De Santi C, Pietrabissa A, Mosca F, et al. Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver. Xenobiotica. 2000;30:1047-1054. (Pubitemid 32099176)
53. Das S, Lin H-S, Ho PC, et al. The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol. Pharm Res. 2008;25:2593-2600.
54. Larrosa M, Tomé-Carneiro J, Yáñez-Gascón MJ, et al. Preventive oral treatment with resveratrol pro-prodrugs drastically reduce colon inflammation in rodents. J Med Chem. 2010;53:7365-7376.
55. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2007;22:659-661.